Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION In a mid-size sponsor after a complete response letter, advisory-committee question list that exposes a weak secondary endpoint is the evidence after an FAERS cluster in a demographic the trials under-enrolled. Pharmacovigilance medical reviewer has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using advisory-committee question list that exposes a weak secondary endpoint.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after an FAERS cluster in a demographic the trials under-enrolled for pharmacovigilance medical reviewer. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision the 505(b)(2) bridge is turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pharmacovigilance medical reviewer would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.